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Foreword 
 
The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 
2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in 
the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The 
publications and other scientific activities included in the evaluation covered the years 2005–2010. 
The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a 
critical mass with university-level impact, the number of members was set to range from 20 to 120. The 
RCs were required to contain researchers in all stages of their research career, from doctoral students to 
principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary 
evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to 
participate in two communities in certain cases, and 72 of them used this opportunity and participated in 
two RCs. 
This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim 
of the evaluation was not to assess individual performance but a community with shared aims and 
researcher-training activities. The RCs were able to choose among five different categories that 
characterised the status and main aims of their research. The steering group considered the process of 
applying to participate in the evaluation to be important, which lead to the establishment of these 
categories. In addition, providing a service for the RCs to enable them to benchmark their research at the 
global level was a main goal of the evaluation. 
The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms 
and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The 
compilation covered scientific and other publications as well as certain areas of scientific activities. During 
the process, the RCs were asked to check the list of publications and other scientific activities and make 
corrections if needed. These TUHAT compilations are public and available on the evaluation project sites 
of each RC in the TUHAT-RIS. 
In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric 
analyses from the articles included in the Web of Science (WoS). This was done on University and RC 
levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the 
Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 
66 RCs representing the humanities and social sciences. 
The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about 
the organisation of doctoral studies at the University of Helsinki. This and other documents describing the 
University and the Finnish higher education system were provided to the panellists. 
The panel feedback for each RC is unique and presented as an entity. The first collective evaluation 
reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all 
panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to 
complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, 
doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for 
participation in the evaluation. Panellists used the international level as a point of comparison in the 
evaluation. Scoring was not expected to go along with a preset deviation. 
Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 
September to 13 September or from 18 September to 20 September 2011). In these meetings the panels 
also examined the deviations among the scores and finalised the draft reports together. 
The current RC-specific report deals shortly with the background of the evaluation and the terms of 
participation. The main evaluation feedback is provided in the evaluation report, organised according to 
the evaluation questions. The original material provided by the RCs for the panellists has been attached to 
these documents. 
 
 
 
 
 
 
 
 
 
On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your 
participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully 
acknowledged by the University. We wish that you find this panel feedback useful in many ways. The 
bibliometric profiles may open a new view on your publication forums and provide a perspective for 
discussion on your choice of forums. We especially hope that this evaluation report will help you in setting 
the future goals of your research. 
 
Johanna Björkroth 
Vice-Rector 
Chair of the Steering Group of the Evaluation 
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CHAIR 
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Karolinska Institute, Sweden 
 
VICE-CHAIR 
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providing the evaluation project with the updated information from TUHAT-RIS. 
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MA Liisa Ekebom, Assisting Officer, served in TUHAT-RIS updating the 
publications for the evaluation. She also assisted the UH/Library analyses. 
BA Liisa Jäppinen, Assisting Officer, served in TUHAT-RIS updating the 
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3 
 
 
Acronyms and abbreviations applied in the report 
 
External competitive funding 
AF – Academy of Finland 
TEKES - Finnish Funding Agency for Technology and Innovation  
EU - European Union 
ERC - European Research Council 
International and national foundations 
FP7/6 etc. /Framework Programmes/Funding of European Commission 
 
Evaluation marks 
Outstanding (5) 
Excellent  (4) 
Very Good  (3) 
Good  (2) 
Sufficient  (1) 
 
Abbreviations of Bibliometric Indicators 
P - Number of publications 
TCS – Total number of citations 
MCS - Number of citations per publication, excluding self-citations 
PNC - Percentage of uncited publications 
MNCS - Field-normalized number of citations per publication 
MNJS - Field-normalized average journal impact 
THCP10 - Field-normalized proportion highly cited publications (top 10%) 
INT_COV - Internal coverage, the average amount of references covered by the WoS 
WoS – Thomson Reuters Web of Science Databases 
 
Participation category 
Category 1. The research of the participating community represents the international cutting edge in its 
field. 
Category 2. The research of the participating community is of high quality, but the community in its 
present composition has yet to achieve strong international recognition or a clear break-through. 
Category 3. The research of the participating community is distinct from mainstream research, and the 
special features of the research tradition in the field must be considered in the evaluation. 
Category 4. The research of the participating community represents an innovative opening. 
Category 5. The research of the participating community has a highly significant societal impact. 
 
Research focus areas of the University of Helsinki 
Focus area 1: The basic structure, materials and natural resources of the physical world 
Focus area 2: The basic structure of life 
Focus area 3: The changing environment – clean water 
Focus area 4: The thinking and learning human being 
Focus area 5: Welfare and safety 
Focus area 6: Clinical research 
Focus area 7: Precise reasoning 
Focus area 8: Language and culture 
Focus area 9: Social justice 
Focus area 10: Globalisation and social change 
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1 Introduction to the Evaluation 
1.1 RC-specific evaluation reports 
The participants in the evaluation of research and doctoral training were Researcher Communities 
(hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the 
evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the 
Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their 
compositions should be considered well-established or new. 
It is essential to emphasise that the evaluation combines both meta-evaluation1 and traditional 
research assessment exercise and its focus is both on the research outcomes and procedures associated 
with research and doctoral training. The approach to the evaluation is enhancement-led where self-
evaluation constituted the main information. The answers to the evaluation questions formed together 
with the information of publications and other scientific activities an entity that was to be reviewed as a 
whole. 
The present evaluation recognizes and justifies the diversity of research practices and publication 
traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with 
low volumes or research distinct from mainstream research. It is challenging to expose the diversity of 
research to fair comparison. To understand the essence of different research practices and to do justice to 
their diversity was one of the main challenges of the present evaluation method. Understanding the 
divergent starting points of the RCs demanded sensitivity from the evaluators. 
1.2 Aims and objectives in the evaluation 
The aims of the evaluation are as follows: 
 to improve the level of research and doctoral training at the University of Helsinki and to raise 
their international profile in accordance with the University’s strategic policies. The improvement 
of doctoral training should be compared to the University’s policy.2 
 to enhance the research conducted at the University by taking into account the diversity, 
originality, multidisciplinary nature, success and field-specificity, 
 to recognize the conditions and prerequisites under which excellent, original and high-impact 
research is carried out, 
 to offer the academic community the opportunity to receive topical and versatile international 
peer feedback, 
 to better recognize the University’s research potential. 
 to exploit the University’s TUHAT research information system to enable transparency of 
publishing activities and in the production of reliable, comparable data. 
1.3 Evaluation method 
The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to 
provide useful information for the enhancement of research and doctoral training of the participating RCs. 
The comparison should take into account each field of science and acknowledge their special character. 
                                                                
1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation 
questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses. 
2
 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.  
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The comparison produced information about the present status and factors that have lead to success. Also 
challenges in the operations and outcomes were recognized. 
The evaluation approach has been designed to recognize better the significance and specific nature of 
researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one 
of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent 
ones. Thus the views of various fields of research can be described and research arising from various 
starting points understood better. The doctoral training is integrated into the evaluation as a natural 
component related to research. Operational processes of doctoral training are being examined in the 
evaluation. 
 
Five stages of the evaluation method were: 
1. Registration – Stage 1 
2. Self-evaluation – Stage 2 
3. TUHAT3 compilations on publications and other scientific activities4 
4. External evaluation 
5. Public reporting 
1.4 Implementation of the external evaluation 
Five Evaluation Panels 
Five evaluation panels consisted of independent, renowned and highly respected experts. The main 
domains of the panels are: 
1. biological, agricultural and veterinary sciences 
2. medicine, biomedicine and health sciences 
3. natural sciences 
4. humanities 
5. social sciences 
The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on 
the suggestions of faculties and independent institutes. Besides leading the work of the panel, an 
additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar 
approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam. 
The panel compositions were nominated by the Rector of the University 27 April 2011. The participating 
RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller 
number of panellists as compared to the previous evaluations was the character of the evaluation as a 
meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated 
answers to the evaluation questions, tables and compilations of publications, other scientific activities, 
bibliometrics and comparable analyses. 
 
The panel meetings were held in Helsinki: 
 On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, 
biomedicine and health sciences and (3) natural sciences.  
 On 18–20 September 2011: (4) humanities and (5) social sciences. 
  
                                                                
3 TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki 
4 Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and 
networks and public appearances. 
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1.5 Evaluation material 
The main material in the evaluation was the RCs’ self-evaluations that were qualitative in character and 
allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned. 
The present evaluation is exceptional at least in the Finnish context because it is based on both the 
evaluation documentation (self-evaluation questions, publications and other scientific activities) and the 
bibliometric reports. All documents were delivered to the panellists for examination. 
Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences 
when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for 
Science and Technology Studies, University of Leiden, cover only the publications that include WoS 
identification in the TUHAT-RIS. 
Traditional bibliometrics are seldom relevant in humanities and social sciences because the 
international comparable databases do not store every type of high quality research publications, such as 
books and monographs and scientific journals in other languages than English. The Helsinki University 
Library has done analysis to the RCs, if their publications were not well represented in the Web of Science 
databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) 
– it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-
specific bibliometric reports are attached at the end of each report. 
The panels were provided with the evaluation material and all other necessary background information, 
such as the basic information about the University of Helsinki and the Finnish higher education system. 
 
Evaluation material 
1. Registration documents of the RCs for the background information 
2. Self evaluation material – answers to the evaluation questions 
3. Publications and other scientific activities based on the TUHAT RIS: 
3.1. statistics of publications 
3.2. list of publications 
3.3. statistics of other scientific activities 
3.4. list of other scientific activities 
4. Bibliometrics and comparable analyses: 
4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web 
of Science publications (CWTS/University of Leiden) 
4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and 
social sciences 
5. University level survey on doctoral training (August 2011) 
6. University level analysis on publications 2005–2010 (August 2011) provided by CWTS/University 
of Leiden 
 
Background material 
 
University of Helsinki 
- Basic information about the University of the Helsinki 
- The structure of doctoral training at the University of Helsinki 
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005 
 
The Finnish Universities/Research Institutes 
- Finnish University system 
- Evaluation of the Finnish National Innovation System 
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 
9/09. 
 
The evaluation panels were provided also with other relevant material on request before the meetings in 
Helsinki. 
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1.6 Evaluation questions and material 
The participating RCs answered the following evaluation questions which are presented according to the 
evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For 
giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line 
with the evaluation questions: 
 
1. Focus and quality of the RC’s research 
 Description of 
- the RC’s research focus. 
- the quality of the RC’s research (incl. key research questions and results) 
- the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data 
(provided by University of Leiden and the Helsinki University Library) 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
2. Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
- recruitment and selection of doctoral candidates 
- supervision of doctoral candidates 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
- good practises and quality assurance in doctoral training 
- assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
3. The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with 
public, private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral 
training. 
The additional material: TUHAT compilation of the RC’s other scientific activities. 
A written feedback from the aspects of: societal impact, national and international collaboration, 
innovativeness 
 
  Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
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4. International and national (incl. intersectoral) research collaboration and researcher mobility 
 Description of  
- the RC’s research collaborations and joint doctoral training activities 
- how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and 
researcher mobility, and the actions planned for their development. 
A written feedback from the aspects of: scientific quality, national and international collaboration 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
5. Operational conditions  
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the 
actions planned for their development. 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
6. Leadership and management in the researcher community 
 Description of 
- the execution and processes of leadership in the RC 
- how the management-related responsibilities and roles are distributed in the RC 
- how the leadership- and management-related processes support 
- high quality research 
- collaboration between principal investigators and other researchers in the RC 
the RC’s research focus 
- strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and 
the actions planned for developing the processes 
 
7. External competitive funding of the RC 
 The RCs were asked to provide information of such external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The 
Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other national funding 
organisations, other international funding organisations), and 
2)The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
 
Competitive funding reported in the text is also to be considered when evaluating this point. 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness, future significance 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
8. The RC’s strategic action plan for 2011–2013 
 RC’s description of their future perspectives in relation to research and doctoral training. 
A written feedback from the aspects of: scientific quality, scientific significance, societal Impact, processes 
and good practices related to leadership and management, national and international collaboration, 
innovativeness, future significance 
 Strengths 
 Areas of development 
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 Other remarks 
 Recommendations 
 
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) 
 
The RC’s fitness to the chosen participation category 
A written feedback evaluating the RC’s fitness to the chosen participation category  
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
10. Short description of how the RC members contributed the compilation of the stage 2 material 
Comments on the compilation of evaluation material 
 
11. How the UH’s focus areas are presented in the RC’s research? 
Comments if applicable 
 
12. RC-specific main recommendations based on the previous questions 1–11 
 
13. RC-specific conclusions 
1.7 Evaluation criteria 
The panellists were expected to give evaluative and analytical feedback to each evaluation question 
according to their aspects in order to describe and justify the quality of the submitted material. In 
addition, the evaluation feedback was asked to be pointed out the level of the performance according to 
the following classifications: 
 outstanding  (5) 
 excellent  (4) 
 very good  (3) 
 good   (2) 
 sufficient  (1) 
 
Evaluation according to the criteria was to be made with thorough consideration of the entire 
evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to 
classify their written feedback into one of the provided levels (the levels included respective descriptions, 
‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the 
integers and not rounding up the decimals by the editors. 
 
Description of criteria levels 
Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Outstandingly strong research, also from international perspective. Attracts great international 
interest with a wide impact, including publications in leading journals and/or monographs published 
by leading international publishing houses. The research has world leading qualities. The research 
focus, key research questions scientific significance, societal impact and innovativeness are of 
outstanding quality. 
In cases where the research is of a national character and, in the judgement of the evaluators, should 
remain so, the concepts of ”international attention” or ”international impact” etc. in the grading 
criteria above may be replaced by ”international comparability”. 
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Operations and procedures are of outstanding quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are in 
alignment with the documentation. The ambition to develop the community together is of 
outstanding quality. 
Excellent quality of procedures and results (4) 
Research of excellent quality. Typically published with great impact, also internationally. Without 
doubt, the research has a leading position in its field in Finland. 
Operations and procedures are of excellent quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of excellent quality. 
Very good quality of procedures and results (3) 
The research is of such very good quality that it attracts wide national and international attention. 
Operations and procedures are of very good quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of very good quality. 
Good quality of procedures and results (2) 
Good research attracting mainly national attention but possessing international potential, 
extraordinarily high relevance may motivate good research. 
Operations and procedures are of good quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to large extent in alignment with the documentation. The ambition to develop the 
community together is of good quality. 
Sufficient quality of procedures and results (1) 
In some cases the research is insufficient and reports do not gain wide circulation or do not have 
national or international attention. Research activities should be revised. 
Operations and procedures are of sufficient quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to some extent in alignment with the documentation. The ambition to develop the 
community together is of sufficient quality. 
 
Question 2 – DOCTORAL TRAINING 
Question 3 – SOCIETAL IMPACT 
Question 4 – COLLABORATION 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Procedures are of outstanding quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are in alignment with the 
documentation. The ambition to develop the community together is of outstanding quality. The 
procedures and results are regularly evaluated and the feedback has an effect on the planning. 
Excellent quality of procedures and results (4) 
Procedures are of excellent quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of excellent quality. The 
procedures and outcomes are evaluated and the feedback has an effect on the planning. 
Very good quality of procedures and results (3) 
Procedures are of very good quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
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management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of very good quality. 
Good quality of procedures and results (2) 
Procedures are of good quality, shared occasionally in the community. The practices and quality of 
doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of good quality. 
Sufficient quality of procedures and results (1) 
Procedures are of sufficient quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are occasionally documented and operations and practices are to some extent in 
alignment with the documentation. The ambition to develop the community together is of sufficient 
quality. 
 
Question 9 – CATEGORY 
Participation category – fitness for the category chosen 
The choice and justification for the chosen category below should be reflected in the RC’s responses to the 
evaluation questions 1–8. 
1. The research of the participating community represents the international cutting edge in its field. 
2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
3. The research of the participating community is distinct from mainstream research, and the special 
features of the research tradition in the field must be considered in the evaluation. The research is 
of high quality and has great significance and impact in its field. However, the generally used 
research evaluation methods do not necessarily shed sufficient light on the merits of the 
research.  
4. The research of the participating community represents an innovative opening. A new opening can 
be an innovative combination of research fields, or it can be proven to have a special social, 
national or international demand or other significance. Even if the researcher community in its 
present composition has yet to obtain proof of international success, its members can produce 
convincing evidence of the high level of their previous research. 
5. The research of the participating community has a highly significant societal impact. The 
participating researcher community is able to justify the high social significance of its research. 
The research may relate to national legislation, media visibility or participation in social debate, 
or other activities promoting social development and human welfare. In addition to having 
societal impact, the research must be of a high standard. 
 
An example of outstanding fitness for category choice (5) 5 
The RC’s representation and argumentation for the chosen category were convincing. The RC recognized 
its real capacity and apparent outcomes in a wider context to the research communities. The specific 
character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the 
category. 
 
 Outstanding  (5) 
 Excellent  (4) 
 Very good  (3) 
 Good   (2) 
 Sufficient  (1) 
The above-mentioned definition of outstanding was only an example in order to assist the panellists in 
the positioning of the classification. There was no exact definition for the category fitness. 
                                                                
5 The panels discussed the category fitness and made the final conclusions of the interpretation of it. 
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1.8 Timetable of the evaluation 
The main timetable of the evaluation: 
1. Registration   November 2010 
2. Submission of self-evaluation materials  January–February 2011 
3. External peer review    May–September 2011 
4. Published reports    March–April 2012 
- University level public report 
- RC specific reports 
 
The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary 
results were available for the planning of the following strategy period in late autumn 2011. The evaluation 
reports will be published in March/April 2012. More detailed time schedule is published in the University 
report. 
1.9 Evaluation feedback – consensus of the entire panel 
The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the 
draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists 
on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft 
reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued 
working and finalised the reports before the end of November 2011. The final RC-specific reports are the 
consensus of the entire panel. 
The evaluation reports were written by the panels independently. During the editing process, the 
evaluation office requested some clarifications from the panels when necessary. The tone and style in the 
reports were not harmonized in the editing process. All the reports follow the original texts written by the 
panels as far as it was possible. 
The original evaluation material of the RCs, provided for the panellists is attached at the end of the 
report. It is essential to notice that the exported lists of publications and other scientific activities depend 
how the data was stored in the TUHAT-RIS by the RCs. 
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2 Evaluation feedback 
2.1 Focus and quality of the RC’s research 
 Description of 
 the RC’s research focus 
 the quality of the RC’s research (incl. key research questions and results) 
 the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness 
 
The RC P-Molmed is formed around PIs working either at the Institute of Molecular Medicine Finland 
(FIMM) or the Faculty of Medicine, University of Helsinki/Helsinki University Hospital. The RC altogether 
has seven research groups, but some of the groups consist of only 1-3 persons. The key focus of the RC is 
personalized molecular medicine. The RC specifically aims to 1) carry out research on personalized 
molecular medicine, 2) create technical expertise and internationally competitive infrastructures for 
facilitating personalized medicine, 3) carry out research training, 4) increase society impact arising out of 
the above, and 5) facilitate implementation of personalized medicine in the health care sector. The 
selected research topics include: 1) predicting the risk of cardiovascular disease by using genomics and 
molecular profiling data from large-scale Finnish population cohorts, 2) developing personalized medicine 
strategies to assess the most optimal therapies to individual leukemia patients, acute myeloid leukemias in 
particular and 3) integrating systems for automated molecular, imaging and clinical decision algorithms in 
cancer. 
The strengths of the RC rely on a very focused research topic with a strong impact on the society, on 
technology platforms it has developed and/or adapted, a combination of basic researchers and clinicians, 
and the extensive research networks it formed. 
The scientific quality of most individual PIs of P-Molmed is excellent, although at this point it is too 
early to evaluate the collaborative efforts of this newly established RC. First or last author papers of the 
PIs have been published in journals including Blood, Genome Biology, Clinical Cancer Research, Oncogene, 
Cancer Research, PloS One and Lancet. It appears that both the quantity and quality of the articles has 
increased during years 2005-2010. 
Numeric evaluation: 4 (Excellent) 
2.2 Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
 recruitment and selection of doctoral candidates 
 supervision of doctoral candidates 
 collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
 good practises and quality assurance in doctoral training 
 assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
 Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
ASPECTS: Processes and good practices related to leadership and management 
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FIMM, and thereby the P-Molmed RC has an excellent structure for recruiting and training PhD students, 
using schemes adapted from the European Molecular Biology Laboratory (EMBL). The entire training 
period is clearly well thought and professionally pursued. The two-step selection process includes 
videoconferencing and on-site interviews of selected candidates and a specific evaluation requested from 
their referees. Students selected first engage in rotational training for 6-9 months, during which they are 
supervised by the research training coordinator and 2-3 group leaders. After this stage, students are 
supervised primarily by one group leader. Supervision involves complete mentoring toward the PhD 
degree, including development of a specific research plan, discussion of results and planning, 
development of communication and presentation skills, and analysis of published literature. A wide array 
of specific educational courses is offered together with local graduate schools, the Nordic EMBL Molecular 
Medicine Network and the TRANSMED translational medicine PhD program operated by the Faculty of 
Medicine. 
The RC activities only started really in 2010, therefore, it does not have a track-record in PhD training. 
It is unclear from the documents, how many doctoral theses the PIs have supervised during 2005-2010. If 
one takes into account the fact that most of the PIs have carried out research at this environment for 
several years, the current number of PhD students (13) sounds low. However, the training program is well-
thought, indeed, and should yield highly educated PhDs in the following years. 
Numeric evaluation: 5 (Outstanding) 
2.3 The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training. 
 Additional material: TUHAT compilation of the RC’s other scientific activities. 
ASPECTS: Societal impact, national and international collaboration, innovativeness 
 
The high societal impact of P-Molmed is one of the strengths of the RC. It appears that apart from 
science, the implications of the findings to the society are of special interest to the RC. This is evidenced 
by networking with Ministers and the European Commission, major companies, hospital directors, other 
health care providers and funders, the Academy of Finland, Tekes, Sitra, patient organizations, ethical 
experts, researchers and physicians active in the area. 
The RC has several ways for collaboration with the industry to promote the application of its research. 
For instance, it works with two national umbrella organizations, Salwe Inc. in the health care sector and 
Tivit in the IT sector as well as with many other private companies to launch collaborative proposals and 
joint work. Furthermore, its newly-funded Innovative Medicines Initiative (IMI) project with the big pharma 
and the European commission (PREDECT), will certainly have societal impact. 
Numeric evaluation: 5 (Outstanding) 
2.4 International and national (incl. intersectoral) research 
collaboration and researcher mobility 
 Description of  
 the RC’s research collaborations and joint doctoral training activities 
 how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and researcher 
mobility, and the actions planned for their development. 
ASPECTS: Scientific quality, national and international collaboration 
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As a member of the Nordic EMBL Partnership of Molecular Medicine, FIMM and its associated RC PIs have 
direct connections to international networks. In addition, the RC is integrated with several technological 
platform programs of the Biocenter Finland and the national and international infrastructures (e.g. EATRIS 
translational research, BBMRI biobanks, ELIXIR bioinformatics and EU-OPENSCREEN chemical biology). 
National research collaboration is promoted by different mechanisms, e.g. by the Academy of Finland 
Centre of Excellence. 
Numeric evaluation: 5 (Outstanding) 
2.5 Operational conditions 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the actions 
planned for their development. 
ASPECTS: Processes and good practices related to leadership and management 
 
The operational infrastructure of FIMM and the Meilahti biomedical campus provides excellent 
surroundings to carry out research on personalized molecular medicine. Importantly, the RC is actively 
developing its own infrastructure such as clinical decision algorithms and web-based data handling and 
analysis. The RC clearly benefits from strong, international-level infrastructures that support its activities 
in biobanking, translational research, bioinformatics, sequencing, high-throughput drug testing etc., in 
which it is actively engaged. 
2.6 Leadership and management in the researcher community 
 Description of  
 the execution and processes of leadership in the RC 
 how the management-related responsibilities and roles are distributed in the RC 
 how the leadership- and management-related processes support 
 high quality research 
 collaboration between principal investigators and other researchers in the RC 
 the RC’s research focus 
 strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and the 
actions planned for developing the processes 
ASPECTS: Processes and good practices related to leadership and management 
 
It appears that the RC leadership is closely tight to the activities of FIMM. As the majority of the PIs are 
employed by FIMM, this appears to be a natural way to organize the management. 
2.7 External competitive funding of the RC 
• The RCs were asked to provide information of such external competitive funding, where: 
• the funding decisions have been made during 1.1.2005–31.12.2010, and  
• the administrator of the funding is/has been the University of Helsinki 
• On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, 
TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other 
national funding organisations, other international funding organizations), and 
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2) The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
Competitive funding reported in the text is also to be considered when evaluating this point. 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance 
 
The extra-mural funding of P-Molmed for years 2005-2010 is appr. 8 Mill €, of which 2.7 Mill € is from 
TEKES and 2.1 Mill € from international sources. Considering the size of the RC the amounts are 
substantial, and indicate the impact of the RC. 
2.8 The RC’s strategic action plan for 2011–2013 
• RC’s description of their future perspectives in relation to research and doctoral training. 
ASPECTS: Scientific quality, scientific significance, societal Impact, processes and good practices related to 
leadership and management, national and international collaboration, innovativeness, future significance 
 
As a recently established RC, the strategic action plan includes executing the activities described in point 
1. (Focus of RCs research). This will include building the research infrastructure, collecting biobank 
material for the goals and carrying out research on risk prediction for cardiovascular disease, developing 
personalized therapy for AML and building automated molecular, imaging and clinical decision algorithms 
in cancer. 
Similarly, the action plan for doctoral training follows the plans described in point 2 (Practises and 
quality of doctoral training). 
2.9 Evaluation of the category of the RC in the context of entity of 
the evaluation material (1-8) 
The RC’s fitness to the chosen participation category. 
Category 5. The research of the participating community has a highly significant societal impact. 
 
The P-Molmed RC clearly fits within the chosen participation category. 
Numeric evaluation: 5 (Outstanding) 
2.10 Short description of how the RC members contributed the 
compilation of the stage 2 material 
All PIs contributed to the evaluation material by providing information of their own research groups. 
Different chapters of the actual text were written by individual PIs and group members based on joint 
agreement. 
2.11 How the UH’s focus areas are presented in the RC’s research 
Focus area 6: Clinical research 
 
The research of P-Molmed falls into the focus area: “health and welfare”, and within several of the key 
focus areas: The basic structure of life (systemic biology and biotechnology) and Clinical research 
(clinical translational medicine, personalized medicine). 
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2.12 RC-specific main recommendations 
— 
2.13 RC-specific conclusions 
— 
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3 Appendices 
A. Original evaluation material 
a. Registration material – Stage 1 
b. Answers to evaluation questions – Stage 2 
c. List of publications 
d. List of other scientific activities 
B. Bibliometric analyses 
a. Analysis provided by CWTS/University of Leiden 
b. Analysis provided by Helsinki University Library (66 RCs) 
 
 
 
 
 
International evaluation of research and doctoral training 
at the University of Helsinki 2005-2010 
 
         RC-SPECIFIC MATERIAL FOR THE PEER REVIEW 
 
 
 
 
NAME OF THE RESEARCHER COMMUNITY:  
Personalized Molecular Medicine (P-Molmed) 
 
LEADER OF THE RESEARCHER COMMUNITY:  
Professor Olli Kallioniemi, Institute of Molecular Medicine Finland (FIMM) 
 
 
RC-SPECIFIC MATERIAL FOR THE PEER REVIEW: 
 Material submitted by the RC at stages 1 and 2 of the evaluation 
- STAGE 1 material: RC’s registration form (incl. list of RC participants in an excel table) 
- STAGE 2 material: RC’s answers to evaluation questions 
 TUHAT compilations of the RC members’ publications 1.1.2005-31.12.2010 
 TUHAT compilations of the RC members’ other scientific activities 1.1.2005-31.12.2010 
 Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010 
(analysis carried out by CWTS, Leiden University) 
NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing 
humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library 
(results available by the end of June, 2011) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Name: Kallioniemi, Olli 
E-mail:  
Phone: +358-50-4150363 
Affiliation: Institute for Molecular Medicine Finland (FIMM) 
Street address: Tukholmankatu 8, 00290 Helsinki 
 
 
Name of the participating RC (max. 30 characters): Personalized Molecular Medicine 
Acronym for the participating RC (max. 10 characters): P-Molmed 
Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training 
activities) on which the RC was formed (MAX. 2200 characters with spaces): This RC on personalized 
molecular medicine is developing next-generation personalized medicine technologies, approaches and 
clinical implementation. The basis for this RC is the significant need at the society level for a profound 
change in the way by which medicine is practised to improve efficacy, reduce ineffective and harmful 
therapies and curtail health care costs.  
 
This RC is based on the research focus of the Institute for Molecular Medicine Finland (FIMM) and at the 
Faculty of Medicine and collaborators elsewhere (such as Helsinki University Hospital, the National Institute 
for Health and Welfare and the VTT Technical Research Centre thereby bridging institutions under three 
different ministries). FIMM is also an international partner research institution of the European Molecular 
Biology Laboratory that is operated by the University of Helsinki. Both FIMM and the Faculty of Medicine of 
the University of Helsinki have set up personalized medicine as one of their key strategic research areas. 
 
Two specific areas within personalized medicine will be specifically investigated: 1) genomic risk factor 
predictors for common diseases and 2) molecular oncology therapy predictions.  
 
While the society impact from these studies may be felt in these areas first, the impact of personalized 
medicine will be critically important across all disease types. Therefore, the researchers will make specific 
efforts to bridge out to the society and facilitate the implementation of personalized medicine. This will 
require a multi-disciplinary, cross-society consensus among biomedical and clinical scientists, other health 
care professionals and institutions, patients and patient organizations, the funding bodies (government/ 
communities), regulatory entities and companies.  
 
1 RESPONSIBLE PERSON 
2 DESCRIPTION OF THE PARTICIPATING RESEARCHER COMMUNITY (RC) 
 
 
2 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
The plan is to make Finland an early adaptor of personalized medicine and forerunner in making use of the 
new possibilities to improve human health. 
 
 
Main scientific field of the RC’s research: medicine, biomedicine and healt sciences 
RC's scientific subfield 1: Oncology 
RC's scientific subfield 2: Cardiac and Cardiovascular System 
RC's scientific subfield 3: --Select-- 
RC's scientific subfield 4: --Select-- 
Other, if not in the list: Genomics, systems biology, translational research 
 
 
Participation category: 5. Research of the participating community has a highly significant societal impact 
Justification for the selected participation category (MAX. 2200 characters with spaces): Health care 
accounts for about 7,5 % of the GDP in Finland, a number which is expected to grow significantly in the 
future due to the aging population on one hand and (bio)medical advances on the other. Indirect 
consequences of health care are much larger than this direct percentage would imply. The way by which 
countries deliver health care and contribute to the well-being of the population is therefore critically 
important. One of the key trends emerging as a possible solution to the health care dilemmas of Western 
society is personalized medicine. Personalized medicine gains strength from the recent advances in 
molecular medicine that has led and will continue to lead to the re-definition of disease. 
 
FIMM and the Faculty of Medicine have assembled an outstanding group of scientists interested in 
translating the personalized medicine research to clinical practice. The two topics to be investigated include 
1) the use of the Finnish population cohorts as a resource to investigate the health impact of single 
nucleotide polymorphisms (SNP) panels and 2) the application of cancer genomics, proteomics and drug 
sensitivity screening as a means to develop individualized therapeutic apporoaches. 
 
For example, a recent study by Ripatti et al. (Lancet, 2010) identified novel genetic determinants of 
cardiovascular disease that were as good as current risk factors. Exploring the use of conventional and 
novel risk determinants would make it possible to tailor preventive measures specifically to the people at 
risk, and even develop genotype-specific preventive approaches.   
 
As a second example, we have developed novel approaches to combine molecular profiling of clinical 
tumor samples (e.g. sarcomas and AML as ongoing pilot studies) with drug sensitivity screening of the 
patient-derived cells and cell lines. We believe that these approaches will in the future help to match new 
treatments and drug combinations with patients most likely to benefit and improve quality of life of cancer 
patients by sparing patients from toxic, unnecessary treatments. This would also improve the effectiveness 
of health care. 
3 SCIENTIFIC FIELDS OF THE RC 
4 RC'S PARTICIPATION CATEGORY 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Public description of the RC's research and doctoral training (MAX. 2200 characters with spaces): 
Personalized medicine is a future trend for medicine, arising from the recent results indicating that the 
definitions of disease need to be thoroughly redefined based on the new molecular understanding. With 
each disease divided into multiple molecular subgroups, we will need significant additional studies to assess 
how the etiology and risk factors need to be considered and how diagnostic procedures and therapeutic 
approaches should be changed to reflect the new understanding of disease heterogeneity and individual 
variability. The next challenge is also to translate the new understanding to the health care practise in pilot 
studies. The hope is that personalized medicine will in the future significantly increase the effectiveness of 
health care and medical practice and result in better health and well-being of the population.   
 
Personalized medicine research and expertise is therefore crucial to the future progress of medicine and it 
is of paramount importance to carry out research in this field, and train the future experts in this field to 
serve in the health care organizations, but also in the government-regulatory functions as well as in the 
private sector. 
Significance of the RC's research and doctoral training for the University of Helsinki (MAX. 2200 
characters with spaces): Personalized medicine is a future trend for medicine, arising from the recent 
results indicating that the definitions of disease need to be thoroughly redefined based on the new 
molecular understanding. With each disease divided into multiple molecular subgroups, we will need 
significant additional studies to assess how the etiology and risk factors need to be considered and how 
diagnostic procedures and therapeutic approaches should be changed to reflect the new understanding of 
disease heterogeneity and individual variability. The next challenge is also to translate the new 
understanding to the health care practise in pilot studies. The hope is that personalized medicine will in the 
future significantly increase the effectiveness of health care and medical practice and result in better health 
and well-being of the population.   
 
Personalized medicine research and expertise is therefore crucial to the future progress of medicine and it 
is of paramount importance to carry out research in this field, and train the future experts in this field to 
serve in the health care organizations, but also in the government-regulatory functions as well as in the 
private sector. 
Keywords: Personalized medicine, molecular medicine, translational research, human genome, molecular 
profiling, medical bioinformatics, predictive genomics, diagnostics, drug sensitivity testing, health care 
efficacy, biobanking 
 
 
Justified estimate of the quality of the RC's research and doctoral training at national and international 
level during 2005-2010 (MAX. 2200 characters with spaces): An internationally significant group of 
scientists and physician scientists has been assembled to lead and participate in this effort with Olli 
5 DESCRIPTION OF THE RC'S RESEARCH AND DOCTORAL TRAINING 
6 QUALITY OF RC'S RESEARCH AND DOCTORAL TRAINING 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
Kallioniemi as Director of FIMM coordinating the effort. We are particularly excited about the recent 
nomination of Jonathan K.C. Knowles as a FiDiPro Professor at FIMM. Jonathan Knowles was previously 
Director of Research at Hoffman La Roche in Basel, and is globally known as a pioneer in personalized 
medicine. His impact in this effort will be critical towards influencing the society and making a big change in 
the field locally, nationally and internationally.  
 
Other key members of this consortium are Professors at the Faculty of Medicine in cancer research and 
molecular oncology, such as Professors Kari Alitalo, Heikki Joensuu and Kimmo Porkka, as well as in the field 
of human genomics professors Jaakko Kaprio and Kimmo Kontula. 
 
At FIMM, many other people will join this effort, including Professor Aarno Palotie and young EMBL-style 
group leaders and senior researchers Samuli Ripatti, Krister Wennerberg, Johan Lundin, Caroline Heckman, 
Gretchen Repasky, Maija Wolf, Kimmo Pitkänen and Imre Västrik. 
Comments on how the RC's scientific productivity and doctoral training should be evaluated (MAX. 2200 
characters with spaces): This new effort is primarily focused at improving society benefits through cutting-
edge research. Therefore, besides the number of dissertations and the quality and number of publications, 
the impact can be felt in terms of educational events, other public events, and contacts with the society, 
newspaper and professional articles, by expansion of biobanking practices, and by the adaptation of the 
personalized medicine by the institutions. 
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: Personalized Molecular Medicine (P-Molmed)
RC-LEADER O. Kallioniemi
CATEGORY 5
Last name First name
PI-status 
(TUHAT-
check, 
lista 29.11.)
Title of research and 
teaching personnel Affiliation 
1 Kallioniemi Olli X Professor FIMM
2 Mpindi John Patrick Doctoral Student FIMM
3 Knowles Jonathan X Professor FIMM
4 Heckman Caroline Senior Researcher FIMM
5 Lundin Johan X Senior Researcher FIMM
6 Linder Nina Postdoctral Researcher FIMM
7 Konsti Juho Doctoral Student FIMM
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Name of the RC’s responsible person: Kallioniemi, Olli 
E-mail of the RC’s responsible person:   
Name and acronym of the participating RC: Personalized Molecular Medicine, P-Molmed 
The RC’s research represents the following key focus area of UH: 6. Kliininen tutkimus – Clinical research 
Comments for selecting/not selecting the key focus area: This new RC on personalized medicine links 
closely to clinical research, but has a much wider reach than that. 
 
The ultimate aim is to impact on the change of health care from the current traditional approach to a more 
targeted, molecularly oriented personalized health care. Health care in the Western world is often 
considered to be in a crisis and at a turning point, with costs that will escalate beyond the capabilities of the 
societies. As explained later, the adoption of personalized medicine will be one of the key factors that must 
happen, and this will impact not just clinical research, but also society at large, including health care 
institutions, patients, healthy people, funders, ministries and political decision makers as well as companies 
active in this area. Therefore, we are not focusing only on traditional medical research, but on impacting 
the society at large by research, research training, information management, and research projects 
focusing on implementation. This is an area where we expect to have a profound change in the society in 
the next five years. 
 
 
 Description of the RC’s research focus, the quality of the RC’s research (incl. key research 
questions and results) and the scientific significance of the RC’s research for the research 
field(s).  
The RC on personalized molecular medicine has its origins in the Institute for Molecular Medicine 
Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine at the University of Helsinki, launched 
just three years ago in 2008. The project on personalized molecular medicine is a flagship project of the 
entire institute, and FIMM is strongly committed to promote this RC. 
 
This RC is a new entity and mostly addressing future challenges. However, in the past 2-3 years, it 
already has had a significant academic and technological track record, including raising funding for the 
RC work. 
 
This RC will address the future challenges of health care by focusing on personalized molecular 
medicine. The RC will include academic research, PhD training and practical implementation and society 
impact going hand in hand. The aims of the RC are as follows: 
1) Carry out research on personalized molecular medicine, with high-profile science and health benefits 
jointly considered. 
2) Create technical expertise and internationally competitive infrastructures for facilitating personalized 
medicine. 
3) Carry out research training. 
4) Increase society impact arising out of the above, by generating capabilities, compelling scientific 
arguments for personalized molecular medicine and increasing awareness 
BACKGROUND INFORMATION 
1 FOCUS AND QUALITY OF RC'S RESEARCH (MAX. 8800 CHARACTERS WITH SPACES) 
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5) Facilitate implementation of personalized medicine in the health care sector at large by creating 
strong networks that involve patients, physicians, health care providers, ministries, companies and other 
key stakeholders. 
 
In this RC, we will focus scientifically initially on three specific research topics, 1) predicting the risk of 
cardiovascular disease by using genomics and molecular profiling data from large-scale Finnish 
population cohorts, 2) developing personalized medicine strategies to asses the most optimal therapies 
to individual leukemia patients, acute myeloid leukemias in particular and 3) integrating systems for 
automated molecular, imaging and clinical decision algorithms in cancer. These research projects are 
meant to provide examples of the concrete future possibilities of personalized medicine and will provide 
a critical mass of experts in research, infrastructure and training. However, these fields will later be 
expanded to other indications, such as other chronic diseases and all types of cancers, with more 
collaborators joining this RC. 
 
The RC will also contribute to key national and international infrastructures to advance personalized 
medicine. In Finland, FIMM is coordinating translational research network under the Biocenter Finland 
umbrella organization and is already a key player in advancing personalized medicine. FIMM is the 
Finnish hub for a international infrastructure network for translational research (EATRIS) and is closely 
involved in the international efforts for biobanking (BBMRI), bioinformatics (ELIXIR) and chemical 
biology (EU-OPENSCREEN). All these fields are particularly critical for advancing the foundations of 
personalized medicine, with particular attention being placed in this RC for making biobanking part of 
the medical care of most patients. 
 
We will use an entirely new strategy to provide feedback from academic research to the clinical 
diagnostic and therapeutic decision making of recurrent and treatment-refractory leukemia patients 
with no evidence-based medicine or other treatment options available. We feel that research and 
clinical medicine have been not only unlinked, but brought miles apart in the regulatory, legal and 
ethical framework in academic hospitals, and it is time to bring them close together. Thus, we will set up 
clinical biobanking of all AML cases throughout Finland, in a manner that the samples are amenable to 
both research studies but also available to clinical diagnostics should it become necessary to e.g. 
compare primary vs. recurrent samples.  Furthermore, we will make the data from the molecular 
profiles of the individual patient cases available to the clinicians. We will also set up personalized 
medicine drug screening to individualize and optimize drug combinations given to patients. Therefore, 
this RC will drive both biobanking practices, as well as a pilot projects in personalized medicine, which 
could both initiate a new wave of thinking and new rapid advances in the adoption of molecular 
medicine. 
 
The scientific significance of the RC's research for the research field(s). 
From the scientific standpoint, the RC is particularly timely as the recent technological developments 
have allowed both normal and cancer genomes being sequenced. For example, at the end of 2010, we 
have already received full genomic sequences from about 100 Finnish individuals. In the next 3-4 years, 
25,000 fully sequenced cancer genomes will be available, along with other molecular profiling data. 
There has been a boom of high-impact publications from human genomics that forms the scientific base 
of this RC. There have been multiple successful efforts (e.g. Ripatti et al., Lancet, 2010) to also advance 
the genetics to clinical use, but this effort is still largely a future goal of the RC. Translating this 
enormous amount of information to the medical practice is one of the most significant challenges of our 
life-time, and will require both new approaches but also a new generation of trained scientists and 
medical professionals, capable of understanding, prioritizing and computerized interpretation of the 
data. Medical decisions at the personalized level will in the future be facilitated and guided (not 
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dictated) by computer-decision based approaches, and therefore increased efforts to facilitate this will 
be urgently needed. 
 
Implementation of personalized medicine in the health care means that we will see the current 
definition of disease based on gross anatomical and physiological means (cancer, cardiovascular disease, 
Alzheimer’s disease, arthritis etc.) to be divided into a number of smaller and smaller molecularly 
defined entities. These entities will eventually complement, if not in many cases replace, the current 
definitions of disease, which date back to the early days of medicine. Therefore, molecular 
understanding is a fundamental first step, but this will not lead anywhere unless we can turn this into a 
diagnostic process that is routinely practiced, and which will impact on therapeutic decisions and will 
eventually lead to improved efficiency of health care. 
 
Finland has been a world leader in human genomics research, with a major strength being in the 
registries, well-educated population, high-quality standardized medical care and a trust to authorities 
and the medical profession. We believe that the same advances will help to propel personalized 
medicine forward in Finland and we have set our goal of making Finland a leading country in 
implementing personalized medicine. 
 Ways to strengthen the focus and improve the quality of the RC’s research. 
Strong collaborations are sought between scientists, clinical experts and patients to advance new types 
of research efforts in personalized medicine. 
 
We will bridge the current, ever-widening gap between biomedical research and health care sector by 
new strategies. For example, our patient consent forms and biobanking procedures will not disconnect 
research and clinical treatment as is usually done, but will allow us to use biobanked specimens for 
clinical diagnostics, and will allow us to pass information to clinicians for consideration as part of 
treatment. 
 
We will enhance educational and society impacts in an interconnected way. The RC will have to address 
not only scientific goals, but extremely complex society questions for changing current practices of 
health care. 
 
We will need world-class experts to give credibility and excitement to the efforts. We are fortunate to 
have Finland Distinguished Professor Jonathan Knowles (former Head of Research at Hoffman La Roche 
in Basel) a globally renowned expert in personalized medicine, as a key contributor. 
 
 
  How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and 
selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, 
departments/institutes, and potential graduate schools/doctoral programmes, good practises and 
quality assurance in doctoral training, and assuring good career perspectives for the doctoral 
candidates/fresh doctorates.  
This RC benefits directly from the research training adapted at FIMM, along with excellent training 
provided by local and national graduate schools, such as the Helsinki Biomedical Graduate School 
(HBGS), national Graduate School of Clinical Investigation (CLIGS), and national school in drug discovery 
and diagnostics, the Drug Discovery Graduate School (DDGS).  As an EMBL-associated international 
molecular medicine institution, FIMM recently adapted the EMBL model for international recruitment of 
new PhD students.  With an announcement, facilitated by the EMBL’s brand name and outreach, we 
2 PRACTISES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES) 
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received 243 PhD student applications from 41 nationalities in the last round.  This number of 
applications is an increase from the first such call last year, which produced 68 applications from 21 
nationalities, demonstrating a significant rise in global visibility and interest in the research programs of 
the Institute.   
 
Recruitment and selection: 
Selection of PhD students at the institute level begins by annual international call, the aim of which is to 
recruit high quality students and provide training, in an EMBL style.  Application review is conducted at 
an institute level by an international committee, including group leaders and the research training 
coordinator. Criteria against which candidates are assessed include:  molecular medicine relevance, 
quality of scientific background, experience, and skills, goals, interest in research at FIMM, 
communication and interpersonal skills, and international experience. 
 
The recruitment process includes several rounds of increasing selectivity.  Applications are first 
examined for relevance, qualifications, and research interests that fit the FIMM profile.  Select 
applicants are reviewed more thoroughly, discussed, and ranked by the committee.  8-15 are selected 
for videoconferencing interview, and the top 5-6 are selected for on-site interviews and a specific 
evaluation requested from their referees.  Interviews occur together in one day and consist of one-on-
one meetings, visits to research groups, candidate scientific presentations, meeting current students, 
and tours.  The performance of the applicants is then discussed and 2-4 are recommended for positions.  
The offers are initially for one year covering the period of early training (6 months; see below) and the 
start of the PhD studies (6 months).  Pending a successful first year, an extended contract is offered. 
 
Supervision: 
Students selected at the institute-level first engage in rotational training for 6-9 months, during which 
they are supervised by the research training coordinator and 2-3 group leaders.  After this stage, 
students are supervised primarily by one group leader.   
 
New students first attend a minisymposium in which group leaders present projects available.  Students 
are then matched to a group for a period of 3 months, a research rotation.  During the last week of the 
rotation, students present their findings in an institute-wide poster session. Prior to the end of the first 
rotation, students are matched for a second 3 month rotation, culminating in talks as part of the FIMM 
seminar series.  Near the end of the second rotation, students select, in cooperation with their rotation 
research mentors and the research training coordinator, a group in which to complete their studies.  If a 
decision cannot be reached or the student would like to gain additional expertise, a third 3 month 
research rotation is possible from which a written report is submitted and selection of a group ensues. 
 
After joining a research group, students are supervised primarily by the group leader.  In some cases, a 
senior or postdoctoral researcher is also involved. Supervision involves complete mentoring toward the 
PhD degree, including development of a specific research plan, discussion of results and planning, 
development of communication and presentation skills, and analysis of published literature.  Students 
also join FIMM by direct recruitment to a research group and do not participate in the research 
rotations decribed above, and these students are supervised by their group leader.   
 
Faculties and graduate schools: 
Students, especially those in this RC apply to, meet the requirements of, and earn their degrees typically 
from the Faculty of Medicine. In addition to joining a faculty at the University, many students apply to 
and are awarded a position in a local or national graduate school such as HBGS.  Through doctoral 
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programs, students are guided in scientific and complementary skills training.  In addition, they are 
required to form a thesis committee and annually assess their progress toward the degree.  In turn, 
supervisors and other FIMM PIs participate in organizing and teaching courses.  Three FIMM researchers 
sit on the HBGS curriculum committee in order to facilitate integrated training.  In the upcoming year, 
courses will be offered by FIMM researchers in functional genomics, personalized medicine, biobanking, 
and pathological imaging.  To better integrate FIMM PhD training with HBGS, we proposed, jointly with 
HBGS, to the Academy of Finland, for several positions in the FIMM-EMBL style allowing students to 
more easily particpate in HBGS curriculum, with the addition of FIMM-specific events of research 
rotations, annual symposia, scientific visits, FIMM seminars, retreats, poster sessions, and journal club 
meetings. 
 
Good practises and quality assurance: 
To ensure good practice and quality, this RC has a highly selective recruitment process and assesses 
student progress through several mechanisms including rotations and reports.  Groups are small, 
allowing close, continued supervision by group leaders and interaction with all group members.  Since 
most students are in a doctoral program, progress is also monitored annually through program-wide and 
thesis committee meetings.  Finally, through seminars and the retreat and the Nordic EMBL Molecular 
Medicine Network (NMMN) meeting in which students, postdoctoral researchers, and group leaders 
from all three Nordic EMBL nodes come together to discuss research projects and tour core 
infrastructure and technologies, students present their findings on a regular basis. All of these efforts 
are geared toward ensuring the highest quality in training.   
 
Assuring career perspectives:  For a strong societal impact, we need to have people educated in 
personalized medicine in all facets of society and the health care system, thus training the future leaders 
in personalized medicine and translational research is of critical importance. The training and 
capabilities of postdoctoral researchers and doctoral and master’s students, must substantially differ 
from those of traditional biomedically trained backgrounds, who often lack strong medical perspectives. 
For example, for research training within this RC and at FIMM in general, we expect students to have 
deep knowledge of not only their research project, but also biobanking and molecular profiling 
technologies and translational/personalized medicine approaches, thereby assuring rich career 
perspectives for these students.  We also collaborate with TRANSMED, a translational medicine and 
research focused Master’s degree program in which some students engage in projects in personalized 
medicine at FIMM and our researchers participate in course instruction.  Finally, while international 
training and PhD education are key, we also must reach out to Finnish MDs and help to steer national 
development and implementation of personalized medicine.  This outreach is of prime importance in 
our future development. 
 RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions 
planned for their development. 
Strengths: EMBL empowered international PhD student recruitment, rotations, training and professional 
training practices, strong links to the local biomedical training (HBGP), national grad schools (e.g. drug 
discovery, diagnostics), combination of high-profile research, technologies and clinical context in the 
FIMM concept. 
 
Challenges: Reaching out to the clinical training and clinical graduate schools, deeper incorporation of 
the RC’s aims into the graduate programs. By far the most significant challenge is the impact on the 
health care system, which we fully realize, and research and training are the best ways to approach this 
in the long run. 
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Actions:  Incorporation of personalized medicine themes into the existing graduate programs, not just 
within this RC, but widely in the Meilahti campus, the clinics, as well as nationally and internationally.  
We will consider the need to set up a specific graduate program along the theme of personalized 
medicine.  Building stronger links to the training of pregraduate, postgraduate, and CME training of 
MDs. 
 
 
 Description of how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector).  
Health care accounts for about 7.5% of the GDP in Finland, with an increasing trend due to the aging 
population. In some countries, this percentage is twice that of Finland. Indirectly via the health and well-
being, the impact of health care to the society is much larger. Therefore, improving efficacy and 
performance of health care has a huge impact. One of the solutions to health care challenges nationally 
and globally is personalized medicine. 
 
Personalized medicine gains strength from the recent advances in molecular medicine that will lead to 
the redefinition of diseases. The other element strongly impacting on the future is the integration of 
medical and molecular information, which must be harnessed, interpreted, made available and acted 
upon in a wise manner. The third trend is increasing awareness and willingness of the patients and 
people to take care of their own health, the application of internet, social media and personalized health 
management and monitoring systems. We will initiate a series of efforts to increase awareness of 
personalized medicine and this RC at the society level. 
 
1) We will engage key stakeholders necessary to adopt personalized medicine to high-level discussions. 
Chancellor of the University of Helsinki will chair a major national symposium and issue invitations to 
high-profile stakeholders, such as Ministers and the European Commission, major companies, hospital 
directors, other health care providers and funders, Academy of Finland, Tekes, Sitra, patient 
organizations, ethical experts, researchers and physicians active in the area, as well as companies. The 
help of the chancellor in advancing this society interaction is critical. The expected outcome of these 
efforts is both significant publicity to the personalized medicine, as well as a series of initiatives, 
practical plans and funding initiatives that will push adaptation of personalized medicine. 
 
2)We will work very closely with national stakeholders in the private sector. Tekes as an applied 
research funding agency is interested in personalized medicine, and will be collaborating in raising 
awareness and links to companies. We will work with two national umbrella organizations, Salwe Inc. in 
the health care sector and Tivit in the IT sector as well as with many other private companies to launch 
collaborative proposals and joint work. We are already engaged in discussions with Duodecim, a not-for 
profit company of the Finnish physicians, with an interest in developing software to assist in future 
personalized treatment decisions. 
 
3) Our newly-funded Innovative Medicines Initiative (IMI) project with the big pharma and the European 
commission (PREDECT), will be a major driver of society impact. 
 
4) We will need to have people educated with the personalized medicine in all levels of the society and 
health care system, thus training the future leaders in personalized medicine is of critical importance. 
 
3 SOCIETAL IMPACT OF RESEARCH AND DOCTORAL TRAINING (MAX. 4400 CHARACTERS WITH SPACES) 
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5) New health care procedures are often initially adopted by individual patients, private clinics, and only 
after that they will be propagated to the public sector. This means that the RC must keep eyes open to 
new ways of translating personalized medicine, beyond interactions with the public university clinic next 
door. 
 Ways to strengthen the societal impact of the RC’s research and doctoral training. 
1) Research planning to more directly address personalized medicine and human health. Our research 
should be published in top journals, but also be of interest to the public and communicated well to the 
media for its immediate health implications. 
 
2) New ideas to solve scientific challenges. For example, we have plans with the European 
Bioinformatics Institute to engage the global biomedical researcher and bioinformatics community to 
interpret complex molecular profiling data from individual patients (see below poin 5). Computerized 
decision making is another field of interest. 
 
3) Patients/ individuals are globally empowered by e.g. internet, social media and home-based and 
patient-initiated health testing. These trends will be taken into account to deliver personalized medicine 
for individuals, not just institutions. 
 
4) We will continue to work with Finnish and international companies to advance the field. Sometimes 
companies to implement the plans may not exist, and we will need to promote launch spin-off 
companies, which likely will play an important role in the process. 
 
 
 
 Description of the RC’s research collaborations and joint doctoral training activities and how the RC 
has promoted researcher mobility.  
The RC is again here benefitting from the launch and concepts of the Institute for Molecular Medicine 
Finland (FIMM) and its Nordic EMBL Partnership for Molecular Medicine. As the RC on personalized 
medicine is the key scientific and society impact focus point of the entire FIMM, we will describe here 
also the FIMM collaborations as they pertain to this RC as well. 
 
FIMM is an international research institute focusing on building a bridge from discovery to medical 
applications. FIMM is part of the Nordic EMBL Partnership for Molecular Medicine, together with the 
European Molecular Biology Laboratory (EMBL), and corresponding Oslo and Umeå centres in Norway 
and Sweden. At the national level, FIMM is a joint research institute of the University of Helsinki, the 
Hospital District of Helsinki and Uusimaa (HUS), the National Institute for Health and Welfare (THL) and 
the VTT Technical Research Centre of Finland. Therefore, FIMM naturally bridges both international and 
national collaboration. FIMM is a unique research institute from the point of view of the intersectoral 
research, which is gaining in importance in Finland. The host institutes of FIMM belong to three 
different Ministries. 
 
This RC is also benefiting from the links of the FIMM National Network for Molecular Medicine, a group 
of 15 top scientists in the field of molecular medicine in Finland. The RC is closely integrated with several 
technological platform programs of the Biocenter Finland (www.bf.fi). As already mentioned, the RC is 
also linked to all the national and international infrastructures (e.g. EATRIS translational research, BBMRI 
biobanks, ELIXIR bioinformatics and EU-OPENSCREEN chemical biology) that strongly support the 
scientific base and international links of the RC and provide significant funding(2,8 M€ for 2011). This RC 
4 INTERNATIONAL AND NATIONAL (INCL. INTERSECTORAL) RESEARCH COLLABORATION AND RESEARCHER 
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is also receiving funding from the Innovative Medicines Initiative (IMI), a joint collaboration of EU’s big 
pharma and researchers (1,4 M€ for 2011-15). 
 
This RC is also jointly developing its research efforts with those of the Faculty of Medicine at the 
University of Helsinki. One of the key focus areas of the Faculty of Medicine and the Hospital District of 
Helsinki and Uudenmaa Hospital research goals is personalized medicine. One of the key programs for 
society impact (e.g. fund raising efforts) at the University of Helsinki is also personalized medicine, so 
this RC is closely linked with the goals of the Meilahti medical research organizations as a whole, 
including benefits to the University of Helsinki directly. 
 
An essential component and a key founding feature of the EMBL, as well as that of FIMM (and 
subsequently this RC), is the international mobility. All our group leaders must have engaged in 
international mobility and most of them are hired directly from abroad (US x 3, Sweden x 1, Luxembourg 
x 1, France x 1). At the moment all positions are open to international applicants, the PhD programs 
advertise globally. We do not yet have statistics for this RC, but at the FIMM level, the staff comes from 
19 nationalities so far. 
 
International Finland Distinquished Professors will be a key asset to drive the goals forward with e.g. 
Jonathan Knowles and Juni Palmgren as examples. 
 RC’s strengths and challenges related to research collaboration and researcher mobility, and the 
actions planned for their development. 
Strengths: International environment resulting from EMBL links and administrative procedures, such as 
recruitment. Under-one-roof concept marrying biobank, molecular medicine research, technology cores 
and translational unit. Links to three ministries, national infrastructures and four ESFRI international 
infrastructures support the strong technological base of the RC. Good existing contacts with the 
companies in the field (e.g. Salwe). FIMM and therefore the RC as a whole are uniquely placed at the 
intersection of the society to tackle key questions of broad nature, such as personalized medicine. 
Challenges and action: Get the multitude of international partnerships better aligned to benefit the core 
mission of the RC. The immediate society impact will first be national, and later international. We will 
work more closely with clinicians at the HUS, but will also directly engage in contacts with private clinics, 
patient organizations and individuals via internet, social media, regular media and respected partners, 
such as Duodecim, the Finnish not-for-profit physician organization. 
 
 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties).  
The RC is based on five research groups at the Institute for Molecular Medicine Finland FIMM 
(Kallioniemi, Knowles, Lundin, Ripatti, Wennerberg) and two at the Faculty of Medicine/HUS (Porkka, 
Mustjoki). The groups were selected based on those who have the most direct links to personalized 
medicine and based on how implementation to the health care sector can most readily be done. 
 
Our goal is to achieve concrete society benefits, and envision that in 5 years from now, our RC, FIMM 
and the Meilahti and Finnish medical community is a world-leader in implementing personalized 
medicine in selected areas of this RC. The three areas of research activity and doctoral training for the 
RC are 1) predicting the risk of cardiovascular disease by using genomics and molecular profiling data 
from large-scale Finnish population cohorts (Ripatti, Knowles, Lundin, Kallioniemi), 2) developing 
5 OPERATIONAL CONDITIONS (MAX. 4400 CHARACTERS WITH SPACES) 
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personalized medicine strategies to asses the most optimal therapies to individual leukemia patients, 
acute myeloid leukemias in particular (Porkka, Mustjoki, Kallioniemi, Wennerberg) and 3) integrated 
systems for automated molecular, imaging and clinical decision algorithms in cancer (Lundin, Ripatti, 
Knowles, Kallioniemi). 
 
All these research efforts will closely link to one another and will provide synergistic support to one 
another. For example, the clinical decision algorithms and web-based data handling and analysis 
technologies initially developed for cancer by Lundin’s group, can be adapted for handling and 
processing information from Ripatti’s efforts in cardiovascular risk predictions and later possibly also in 
leukemias.  Most of the researchers at FIMM are engaged in this research with 100% commitment, 
while clinical researchers (Porkka, Mustjoki) will need to manage the clinical duties as well. 
 
As explained above for infrastructures, the RC is benefitting from enormously strong, international-level 
infrastructures that support its activities in biobanking, translational research, bioinformatics, 
sequencing, high-throughput drug testing etc. The RC is also gaining strength from FIMM’s role at the 
intersection of biomedical research, translational research, public health and clinical research and 
practical health care, with links to the programs run by three different Ministries. 
 RC’s strengths and challenges related to operational conditions, and the actions planned for their 
development. 
Strengths: Strong links to FIMM science, technologies, biobanking and translational unit. Links to 
international infrastructures, with a unique intersection between four international ESFRI efforts, 
biobanking, translation, bioinformatics and chemical biology. RC is positioned at the intersection 
between health and research. 
Challenges: Impacting a change in the medical profession is difficult and slow, as the fields is complex 
and often conservative. Scientific evidence is need to drive the change. 
Actions: We need larger networks than the present 7 group leaders to initiate any change in the medical 
sector. Therefore, the RC’s society impact will be done with a much larger network than described here. 
For example, although not formally part of the RC, the rest of the FIMM group leaders are also linked to 
the RC’s future activities, and we also plan to widely collaborate with the Faculty of Medicine as well as 
with HUS, THL and VTT partner institutes of FIMM, and then engage all the society stake-holders into a 
discussion. Chancellor has promised to help in society interaction. 
 
 
 
 Description of the execution and processes of leadership in the RC, how the management-related 
responsibilities and roles are distributed in the RC and how the leadership- and management-related 
processes support high quality research, collaboration between principal investigators and other 
researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.  
The leadership of this RC will be tightly linked with the operational activities of the Institute for 
Molecular Medicine Finland (FIMM), where RC coordinator Olli Kallioniemi is a Director, and where all 
the RC’s group leaders are directly linked with (Knowles FiDiPro Professor, Ripatti and Wennerberg as 
FIMM-EMBL Group Leaders, Lundin to-be-nominated as a Research Director 2/2011, Porkka is a board 
member at FIMM and close collaborator along with Satu Mustjoki whose primary affiliation is at the 
Faculty of Medicine and HUS). 
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The project on personalized molecular medicine is a flagship project of the entire institute, and 
therefore FIMM is strongly committed to promote this RC. The RC will therefore benefit from the 
executional, administrative, infrastructural and collaborative capabilities that FIMM has generated. In 
particular, the area of society impact is such that a loose academic research collaborative group will not 
otherwise have the capability to act as a major player with a strong society interaction. Having the FIMM 
support will be critical towards advancing the society impact that this RC wants to accomplish. 
 
Although the RC is strongly scientifically focused on the three goals indicated, these only serve as 
examples and concrete projects that help to demonstrate the benefits of personalized molecular 
medicine. Changes are needed in most areas of the medical profession and health care, but obviously 
some areas of medicine need to show the way. For example, we have selected hematology and 
leukemias as examples, as this area of medicine has by far the longest track record in propagating 
personalized molecular medicine. 
 RC’s strengths and challenges related to leadership and management, and the actions planned for 
developing the processes. 
Our RC is uniquely positioned in generating society impact and influencing heath care policies based on 
a strong track record of scientific achievements, technological expertise, availability of biobanks and 
registry data in Finland, information management (e.g. Johan Lundin and Samuli Ripatti), links to 
medical profession (e.g. Kimmo Porkka), industrial and society impact (e.g. Jonathan Knowles). 
 
We will create a number of new ideas to solve scientific challenges in personalized medicine and to 
drive the society impact. For example, with the European Bioinformatics Institute, we have plans to 
engage the global biomedical researcher and bioinformatics community to interpret complex molecular 
profiling data from individual patient samples (anonymous with patient consent and ethical review) and 
communicate the findings back to the physicians in real time to help treatment of difficult cases. 
 
 
 
 Listing of the RCs external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 
 Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC 
members during 1.1.2005-31.12.2010: 803240 
 
 Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) 
TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010: 2718000 
 
 European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members 
during 1.1.2005-31.12.2010: 2104330 
 
 European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the 
RC members during 1.1.2005-31.12.2010: 0 
 
 International and national foundations – names of international and national foundations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros).  
- names of the foundations: American Thoracic Society - LAM Treatment Alliance 
7 EXTERNAL COMPETITIVE FUNDING OF THE RC 
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- Cancer Foudation 
- Jane and Aatos Erkko Foundation 
- Hengityssairauksien tutkimussäätiö 
- K.A. Johansson Foundation 
- Sigrid Jusélius Foundation 
- Väinö and Laina Kivi Foundation 
- The LAM Foundation 
- Veritautien Tutkimussäätiö 
- total amount of funding (in euros) from the above-mentioned foundations: 844950 
 
 Other international funding - names of other international funding organizations which have decided to 
allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in 
euros). 
- names of the funding organizations:  
- total amount of funding (in euros) from the above-mentioned funding organizations:  
 
 Other national funding (incl. EVO funding and Ministry of Education and Culture funded doctoral 
programme positions) - names of other national funding organizations which have decided to allocate 
funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros). 
- names of the funding organizations: Ministry of Education and Culture 
- Biocenter Finland 
- Biocentrum Helsinki 
- HUS (EVO Funding) 
- total amount of funding (in euros) from the above-mentioned funding organizations: 1533000 
 
 
 
 Description of the RC’s future perspectives in respect to research and doctoral training. 
As the RC is new, and activities only started really in 2010, most of the description above has focused on 
the future plans, not past achievements. The main points of the research activities are summarized 
below for 2011-2013: 
 
- We will formally launch and execute all the three subprojects, with clear goals defined for biobanks, 
science, technologies, translational aims, education and society impact. 
 
- In the subproject on 1) predicting the risk of cardiovascular disease by using genomics and molecular 
profiling data from large-scale Finnish population cohorts (Ripatti, Knowles, Lundin, Kallioniemi), we will 
try to achieve a concrete understanding of the combined role of genetics and metabolic profiling in 
predicting risk to cardiovascular disease. We will impact on the society by defining practical 
implementation of personalized risk factor estimations for cardiovascular disease on the web, intended 
for lay audience, along with a clinician support tool to integrate risk factors for nutritional and medical 
interventions. 
 
- In the subproject 2) developing personalized medicine strategies to asses the most optimal therapies 
to individual leukemia patients, acute myeloid leukemias in particular (Porkka, Mustjoki, Kallioniemi, 
Wennerberg) we will develop nation-wide biobanking of AMLs, comprehensive molecular profiles of 
8 RC’S STRATEGIC ACTION PLAN FOR 2011–2013 (MAX. 4400 CHARACTERS WITH SPACES) 
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patients, testing for drug sensitivity  and integration of all data into an information management system 
for guiding personalized AML therapy in partice in the participating centres. 
 
- In the subproject 3) integrated systems for automated molecular, imaging and clinical decision 
algorithms in cancer (Lundin, Ripatti, Knowles, Kallioniemi), we will work based on Lundin group’s 
expertise on imaging and web-based tools to link molecular, pathological (imaging) and clinical data 
together on 1000s of patients. The current tools have been best implemented in breast cancer (Finprog 
study), but will be expanded here to prostrate cancer as well as the cardiovascular disease risk factors 
indicated above. 
 
- In all the 3 projects above, we will try to achieve and make available, all the molecular profiling tools 
that might help the patients and the clinicians in treatment selection. 
 
 
 
All group leaders contributed to the joint strategy of the RC and agreed upon the basic profiles of the 
RC. All group leaders provided information on their own group’s activities, and funding details. Olli 
Kallioniemi wrote the basic text on the RC overall plans, with Gretchen Repasky contributing to the 
educational part, Kimmo Pitkänen and Imre Västrik on society interaction, Jonathan Knowles on the 
importance of personalized medicine, Samuli Ripatti on cardiovascular plans and  Johan Lundin on 
imaging, informatics and clinical decision making. Most group leaders provided feedback on the written 
report. FIMM administrative support was critical for personnel, financial and other details. 
9 SHORT DESCRIPTION OF HOW THE RC MEMBERS HAVE CONTRIBUTED TO THE COMPILATION OF THE STAGE 2 
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1 Analysis of publications 
 
- Associated person is one of Olli-Pekka Kallioniemi ,  John Patrick Mpindi ,  Jonathan Knowles , 
 Caroline Heckman ,  Johan Edvard Lundin ,  Nina Linder ,  
Juho Petteri Konsti ,  Tiina Elina Lehtimäki ,  Mikael Edvard Lundin ,  Kimmo Porkka , 
 Satu Mustjoki ,  Jukka Matti Vakkila ,  Anna Kreutzman ,  
Samuli Olli Ripatti ,  Emmi Tikkanen ,  Krister Wennerberg ,  Gretchen Repasky , 
 Leena Karhinen ,  Tonge Brunhilda Ebai , Arnoldus Johannes - Arjan van Adrichem , 
 
 
                                                                           Publication Year 
Publication type 2005 2006 2007 2008 2009 2010 
Total Count 2005 - 
2010 
A1 Refereed journal article 16 11 13 21 26 47 134 
A2 Review in scientific journal     1  1 
A3 Contribution to book/other compilations (refereed)   4    4 
A4 Article in conference publication (refereed)   2  2 2 6 
B1 Unrefereed journal article   1 1 3  5 
B2 Contribution to book/other compilations (non-refereed)     1  1 
B3 Unrefereed article in conference proceedings      1 1 
D1 Article in professional journal      2 2 
H1 Patents   1    1 
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2 Listing of publications 
A1 Refereed journal article 
2005 
Heinonen, M, Bono, P, Narko, K, Chang, S, Lundin, J, Joensuu, H, Furneaux, H, Hla, T, Haglund, C, Ristimäki, A  2005, 'Cytoplasmic 
HuR expression is a prognostic factor in invasive ductal breast carcinoma',  Cancer Research, vol 65, no. 6, pp. 2157-2161. 
Helin, H, Lundin, M, Lundin, J, Martikainen, P, Tammela, T, Helin, H, van der Kwast, T, Isola, J 2005, 'Web-based virtual microscopy in 
teaching and standardizing Gleason grading', Human Pathology, vol 36, no. 4, pp. 381-386. 
Junttila, TT, Sundvall, M, Lundin, M, Lundin, J, Tanner, M, Harkonen, P, Joensuu, H, Isola, J, Elenius, K  2005, 'Cleavable ErbB4 isoform 
in estrogen receptor-regulated growth of breast cancer cells', Advances in Cancer Research, vol 65, pp. 1384-1393. 
Juuti, A, Nordling, S, Lundin, J, Louhimo, J, Haglund, C 2005, 'Syndecan-1 expression: a novel prognostic marker in pancreatic cancer', 
Oncology, vol 68, no. 2/3, pp. 97-106. 
Juuti, A, Nordling, S, Lundin, J, Louhimo, J, Haglund, C 2005, 'Syndecan-1 expression - A novel prognostic marker in pancreatic 
cancer', Oncology, vol 68, pp. 97-106. 
Kallioniemi, O 2005, 'Functional genomics and transcriptomics of prostate cancer: promises and limitations', BJU International, vol 96, 
pp. 10-15. 
Karhinen, L, Nunes Bastos, R, Jokitalo, E, Makarow, M 2005, 'Endoplasmic reticulum exit of a secretory glycoprotein in the absence of 
Sec24p family proteins in yeast', Traffic, vol 5, no. 7, pp. 562-574. 
Kilpivaara, O, Bartkova, J, Eerola, H, Syrjäkoski, K, Vahteristo, P, Lukas, J, Blomqvist, C, Holli, K, Heikkilä, P, Sauter, G, Kallioniemi, O, 
Bartek, J, Nevanlinna, H 2005, 'Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics 
among unselected breast cancer patients', International Journal of Cancer, vol 113, no. 4, pp. 575-580. 
Linder, N, Lundin, J, Isola, J, Lundin, M, Raivio, K, Joensuu, H 2005, 'Down-regulated xanthine oxidoreductase is a feature of 
aggressive breast cancer', Clinical Cancer Research, vol 11, no. 12, pp. 4372-4381. 
Linder, N, Haglund, C, Nordling, S, Lundin, M, Raivio, K, Lundin, J 2005, 'Decreased xanthine oxidoreductase is a predictor of poor 
prognosis in early stage gastric cancer', EJC supplements, vol 3, pp. 216-216. 
Lundan, T, Volin, L, Ruutu, T, Knuutila, S, Porkka, K 2005, 'Allogeneic stem cell transplantation reverses the poor prognosis of CML 
patients with deletions in derivative chromosome 9', Leukemia, vol 19, no. 1, pp. 138-140. 
Rokman, A, Baffoe-Bonnie, AB, Gillanders, E, Fredriksson, H, Autio, V, Ikonen, T, Gibbs, KD, Jones, MP, Gildea, D, Freas-Lutz, D, 
Markey, C, Matikainen, MP, Koivisto, PA, Tammela, TLJ, Kallioniemi, OP, Trent, J, Bailey-Wilson, JE, Schleutker, J 2005, 'Hereditary 
prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus', Human Genetics, vol 116, no. 1-2, pp. 43-50. 
Sivula, A, Talvensaari-Mattila, A, Lundin, J, Joensuu, H, Haglund, C, Ristimäki, A, Turpeenniemi-Hujanen, T  2005, 'Association of 
cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer',  Breast Cancer Research and Treatment, vol 
89, no. 3, pp. 215-220. 
Skotheim, RI, Lind, GE, Monni, O, Nesland, JM, Abeler, VM, Fossa, SD, Duale, N, Brunborg, G, Kallioniemi, O, Andrews, PW, Lothe, 
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development', Cancer Research, vol 65, no. 13, pp. 5588-5598. 
Vakkila, J, Thomson, AW, Hovi, L, Vettenranta, K, Saarinen-Pihkala, UM, Saarinen-Pihkala, U 2005, 'Circulating dendritic cell subset 
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Wiksten, J, Lundin, J, Nordling, S, Kokkola, A, Stenman, U, Haglund, C 2005, 'High tissue expression of tumour-associated trypsin 
inhibitor (TATI) associates with a more favourable prognosis in gastric cancer', Histopathology, vol 46, no. 4, pp. 380-388. 
2006 
Helin, H, Lundin, M, Laakso, M, Lundin, J, Helin, HJ, Isola, J 2006, 'Virtual microscopy in prostate histopathology: simultaneous viewing 
of biopsies stained sequentially with hematoxylin and eosin, and alpha-methylacyl-coenzyme A racemase/p63 immunohistochemistry',  
Journal of Urology, vol 175, no. 2, pp. 495-499. 
Juuti, A, Lundin, J, Nordling, S, Louhimo, J, Haglund, C 2006, 'Epithelial MMP-2 expression correlates with worse prognosis in 
pancreatic cancer', Oncology, vol 71, no. 1-2, pp. 61-68. 
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'Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray 
analyses', Oncogene, vol 2006, no. 52, pp. 6997-7008. 
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Aebersold, R, Kallioniemi, O, Zupan, B 2009, 'Report on EU-USA workshop: how systems biology can advance cancer research (27 
October 2008)', Molecular oncology., vol 3, no. 1, pp. 9-17. 
Lundin, J 2009, 'Pionjärer i global hälsa: [ledare]', Finska Läkaresällskapets Handlingar, vol 169, no. 2, pp. 2-3. 
Lundin, J 2009, 'Kommunikationens olidliga lätthet: [ledare]', Finska Läkaresällskapets Handlingar, vol 169, no. 1, pp. 2. 
B2 Contribution to book/other compilations (non-refereed) 
2009 
Heckman, CA, Holopainen, TT, Alitalo, K 2009, 'Molecular Targeting of Lymphangiogenesis and Tumor Metastasis', in L Stanley (ed.), 
From Local Invasion to Metastatic Cancer , Humana Press, pp. 283-295. 
B3 Unrefereed article in conference proceedings 
2010 
Konsti, J, Lundin, M, Joensuu, H, Lundin, J 2010, Automated vision quantitative assessment of Ki-67 proliferation index in a nationwide 
series of patients with breast cancer,, Virchows Archiv 457 SPRINGER. 
D1 Article in professional journal 
2010 
Kere, J, Ripatti, SO, Perola, M 2010, 'Monitekijäisten tautien genetiikka', Duodecim, vol 126, no. 19, pp. 2305-2310. 
Myllykangas, LT, Paunio, T, Lundin, JE, Marjamaa, A, Silander, K, Pennanen, P, Aarnio, M, Oksanen, MK, Dias, J, Pesonen, S, 
Hemminki, AE 2010, 'Ulkomaiset lääkärit, hammaslääkärit ja tieteelliset jatko-opiskelijat Suomessa', Suomen lääkärilehti , vol 41, pp. 
3309-3314. 
H1 Patents 
2007 
Laakkonen, PM, Porkka, K, Hoffman, JA, Ruoslahti, E 2007, Peptides that home to tumor lymphatic vasculature and methods of using 
same, 7671021. 
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1 Analysis of activities 2005-2010 
 
- Associated person is one of Olli-Pekka Kallioniemi ,  John Patrick Mpindi ,  Jonathan Knowles , 
 Caroline Heckman ,  Johan Edvard Lundin ,  Nina Linder ,  
Juho Petteri Konsti ,  Tiina Elina Lehtimäki ,  Mikael Edvard Lundin ,  Kimmo Porkka , 
 Satu Mustjoki ,  Jukka Matti Vakkila ,  Anna Kreutzman ,  
Samuli Olli Ripatti ,  Emmi Tikkanen ,  Krister Wennerberg ,  Gretchen Repasky , 
 Leena Karhinen ,  Tonge Brunhilda Ebai , Arnoldus Johannes - Arjan van Adrichem , 
 
 
Activity type Count 
Prizes and awards 4 
Editor of research journal 1 
Peer review of manuscripts 8 
Membership or other role in review committee 4 
Membership or other role in research network 4 
Membership or other role in national/international committee, council, board 19 
Membership or other role of body in private company/organisation 1 
Participation in interview for written media 13 
Participation in radio programme 1 
Participation in TV programme 2 
Participation in interview for web based media 1 
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2 Listing of activities 2005-2010 
Prizes and awards 
Olli-Pekka Kallioniemi ,  
AACR Team Science Award, Olli-Pekka Kallioniemi, 2008 
IFCC Abbott Award, Olli-Pekka Kallioniemi, 2008 
Johan Edvard Lundin ,  
Educational Technology Award, Johan Edvard Lundin, 01.01.2005  31.12.2011, Finland 
Best Presentation at a Scientific Session, Johan Edvard Lundin, 20.09.2010, United States 
Editor of research journal 
Johan Edvard Lundin ,  
Editor-in-Chief, Finska Läkaresällskapets Handlingar, Johan Edvard Lundin, 01.01.2005  31.12.2010 
Peer review of manuscripts 
Johan Edvard Lundin ,  
Reviewer, European Journal of Cancer, Johan Edvard Lundin, 01.01.2004  … 
Samuli Olli Ripatti ,  
Reviewed manuscripts for the Alcoholism: Clinical and Experimental Research, Samuli Olli Ripatti, 2005  2010 
Reviewed manuscripts for the Biometrical Journal, Samuli Olli Ripatti, 2005  2010 
Reviewed manuscripts for the Biostatistics Journal, Samuli Olli Ripatti, 2005  2010 
Reviewed manuscripts for the European Journal of Human Genetics, Samuli Olli Ripatti, 2005  2010 
Reviewed manuscripts for the Genetic Epidemiology, Samuli Olli Ripatti, 2005  2010 
Reviewed manuscripts for the Journal of Computational and Graphical Statistics, Samuli Olli Ripatti, 2005  2010 
Reviewed manuscripts for the Lifetime Data Analysis Journal, Samuli Olli Ripatti, 2005  2010 
Membership or other role in review committee 
Johan Edvard Lundin ,  
Tuumorikudoksen geeniprofilointiin perustuvat testit rintasyövän hoidossa, Johan Edvard Lundin, 24.08.2010  …, Finland 
Samuli Olli Ripatti ,  
Member in review committee: ZonMW, Samuli Olli Ripatti, 2007  … 
ERC Advance Grant referee, Samuli Olli Ripatti, 2009  …, Belgium 
ERC starting grant referee, Samuli Olli Ripatti, 2009  …, Belgium 
Membership or other role in research network 
Samuli Olli Ripatti ,  
Member in Nordic Center of Excellence for Disease Genetics: Harmonization of control database, Samuli Olli Ripatti, 2007  2010 
Network in Academia:P3G, Working Group 2, Samuli Olli Ripatti, 2008  … 
Project manager in Biostatistics group (GENESTAT) in EU FP6 coordinated action PHOEBE, Samuli Olli Ripatti, 2008  2009 
Steering Group Member in EU FP7 project ENGAGE, cardiovascular risk factors, statistical genetics, Samuli Olli Ripatti, 2008  … 
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Membership or other role in national/international committee, council, board 
Olli-Pekka Kallioniemi ,  
AACR, Olli-Pekka Kallioniemi, 2001  …, United States 
Human Protein Atlas Initiative, Olli-Pekka Kallioniemi, 2006  …, Sweden 
CREATE-Health, Olli-Pekka Kallioniemi, 2007  …, Sweden 
International Cancer Genome Sequencing Consortium, Olli-Pekka Kallioniemi, 2007  2008 
Biocenter Finland, Olli-Pekka Kallioniemi, 2008  …, Finland 
Biocentrum Helsinki, Board member, Olli-Pekka Kallioniemi, 2008  …, Finland 
ESFRI, Olli-Pekka Kallioniemi, 2008  … 
HBGS, Olli-Pekka Kallioniemi, 2008  …, Finland 
Nordic EMBL, Olli-Pekka Kallioniemi, 2008  … 
Oslo Cancer Biomedicine Consortium, Olli-Pekka Kallioniemi, 2008  …, Norway 
University of Helsinki, Olli-Pekka Kallioniemi, 2008  …, Finland 
AACR, Olli-Pekka Kallioniemi, 2009  …, United States 
EBI-EMBL, Olli-Pekka Kallioniemi, 2009  … 
ERI-ICP, Olli-Pekka Kallioniemi, 2009  … 
European Academy of Cancer Societies, Olli-Pekka Kallioniemi, 2009  … 
WIN Consortium, Olli-Pekka Kallioniemi, 2009  … 
AACR, Olli-Pekka Kallioniemi, 2010  …, United States 
BF, Drug Discovery and Chemical Biology Initiative DDCB, Olli-Pekka Kallioniemi, 2010  …, Finland 
German Consortium for Translational Cancer Research, Olli-Pekka Kallioniemi, 2010  2011, Germany 
Membership or other role of body in private company/organisation 
Johan Edvard Lundin ,  
American Medical Informatics Association, Johan Edvard Lundin, 05.02.2006  31.12.2011, United States 
Participation in interview for written media 
Olli-Pekka Kallioniemi ,  
New law to set up genetic bank, Olli-Pekka Kallioniemi, 04.2009, Finland 
Academy of Finland, Science Breakfast: Henkilökohtainen lääketiede avaa tietä yksilöllisille hoidoille, Olli-Pekka Kallioniemi, 
18.11.2010, Finland 
Maailman tutkituin syöpä, Olli-Pekka Kallioniemi, 15.10.2010, Finland 
Syövän hoitoa räätälöidyisti, Olli-Pekka Kallioniemi, 07.2010, Finland 
Jonathan Knowles ,  
Academy of Finland, Science Breakfast: Henkilökohtainen lääketiede avaa tietä yksilöllisille hoidoille, Jonathan Knowles, 18.11.2010 
Laboratoriolääketiede ja näyttely 2010, Jonathan Knowles, 2010 
Lääke, sijoitus terveyteen ja työkykyyn, Jonathan Knowles, 2010, Finland 
Maailman tutkituin syöpä, Jonathan Knowles, 2010 
Medical research afternoon for science journalists, Jonathan Knowles, 2010 
Tautigeenitieto auttaa sairauksien hoidossa, Jonathan Knowles, 03.10.2010, Finland 
Samuli Olli Ripatti ,  
Interview in "Ajassa" magazine "Ambassador of genes", personal profile of Samuli Ripatti, Samuli Olli Ripatti, 09.2010  … 
Interview in Tiede magazine ("Science"): "Where do Finns come from?",, Samuli Olli Ripatti, 09.2010 
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Samuli Ripatti´s Interview in Helsingin Sanomat about the origin on Finns and 1000 genomes project, Samuli Olli Ripatti, 17.03.2010 
Participation in radio programme 
Samuli Olli Ripatti ,  
Samuli Ripatti´s interview in Finnish National Radio1, Reseptori Science Program about "Finnish genes", Samuli Olli Ripatti, 07.07.2010 
Participation in TV programme 
Samuli Olli Ripatti ,  
Interview in seven o´clock news in MTV3 Finnish National TV, Samuli Olli Ripatti, 16.03.2010 
TV program "Puoli seitsemän", Samuli Olli Ripatti, 14.04.2010 
Participation in interview for web based media 
Jonathan Knowles ,  
Månadens porträtt, Jonathan Knowles, 2010, Sweden 
 
 
 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING  
AT THE UNIVERSITY OF HELSINKI  
Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010  
by CWTS, Leiden University, the Netherlands 
Research Group: Kallioniemi O 
Basic statistics 
Number of publications (P) 119 
Number of citations (TCS) 1,524 
Number of citations per publication (MCS)  13.48 
Percentage of uncited publications 28% 
Field-normalized number of citations per publication (MNCS)   2.88 
Field-normalized average journal impact (MNJS)   2.22 
Field-normalized proportion highly cited publications (top 10%)   3.08 
Internal coverage    .93 
 
Trend analyses 
 
MNCS 
 
THCP10 
 
MNJS 
Collaboration 
 
Performance (MNCS) by collaboration type 
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